Endocrine Abstracts

Background: Despite receiving biochemically adequate levothyroxine replacement, many patients with primary hypothyroidism suffer from persistent symptoms and a reduced quality of life (QoL). The underlying causes of this phenomenon are not fully understood, but psychological factors, autoimmune inflammation, and variations in thyroxine conversion have all been suggested as potential contributors. At this time, however, there is no consensus on the root cause.<p class="abst...

Background: The ’three-genes’ (SFN, MRC2, HMGA2) might have direct role in various cancer progression and malignant thyroid conditions. We previously reported an increased expression of 1,25-D3 neutralizing enzyme, (24-hydroxylase – CYP24A1) as a possible novel marker gene in thyroid carcinoma. In this study, we examined the transcription activity of CYP24A1 and ‘three-genes’ in four functional subgroups of papillary thyroid tumor (PTC)....

Cold nodules are one of the most common findings on scintigraphic examinations of the thyroid gland. About 5–10% of these nodules turn out to be histologically malignant. Our aim was to examine some somatogenetic alterations associated with thyroid cancer in FNA samples of the thyroid. These alterations included single nucleotide mutations (BRAF, HRAS, NRAS, KRAS) and genetic translocations (RET/PTC1, RET/PTC3, PAX8ex7/PPARgamma, PAX8ex9/PPARgamma). The SNPs were tested b...

Cold nodules are one of the most common findings on scintigraphic examinations of the thyroid gland. About 5–10% of these nodules turn out to be histologically malignant. Our aim was to examine some somatogenetic alterations associated with thyroid cancer in FNA samples of the thyroid. These alterations included single nucleotide mutations (BRAF, HRAS, NRAS, KRAS) and genetic translocations (RET/PTC1, RET/PTC3, PAX8ex7/PPARgamma, PAX8ex9/PPARgamma). The SNPs were tested b...

Background: Conventional therapy for chronic hypoparathyroidism (cHP) is often unable to maintain stable normal serum calcium (Ca) levels for a full 24 h, to control symptoms, to prevent the detrimental long-term effects on the kidney and to preserve normal bone architecture. Eneboparatide (AZP-3601) is a novel 36-amino-acid peptide specifically designed to activate the R0 conformation of the PTH receptor 1, that results in a prolonged calcemic response and a sustai...

Background: Conventional therapy with oral calcium (Ca) and active vitamin D (vitD) supplementation for chronic hypoparathyroidism (cHP) can induce or aggravate hypercalciuria and may lead to detrimental long-term renal complications. Eneboparatide (AZP-3601) is a novel 36-amino-acid peptide with a short half-life designed to activate the R0 conformation of the PTH 1 receptor which produces a prolonged calcemic response. This phase 2a study examined the effects of e...